Forbion raises €1.35bn across two funds

Both funds, the early stage Forbion Ventures Fund VI (€750m) and the Forbion Growth Opportunities Fund II (€600m), which will invest up to €70m in up to 15  late stage companies, exceeded their original target sizes and represent Forbion’s largest fundraising success to date. Investments of the Forbion Ventures Fund VI include ADC maker Pheon Therapeutics Ltd (UK), AI protein design specialist Seamless Therapeutics (Germany), and ABC transporter specialist Rectify Pharma Inc. (US).

The Forbion Ventures Fund VI will build a portfolio of highly impactful therapeutics companies including existing biotechs and new companies (co-) founded by Forbion, created around assets sourced from pharma or academic institutions, or around proven management teams. Forbion’s Ventures Fund VI builds on the firm’s strong track record from previous Forbion Ventures funds. Forbion Ventures Fund VI saw a strong re-up rate by existing investors, and at the same time has attracted several new investors including Dutch pension funds PME and PMT, Loyola University of Chicago, the Scott Trust Endowment Ltd and Pictet Alternative Advisors.

The Forbion Growth Opportunities Fund II is focused on investing primarily in European later-stage biopharma companies developing novel therapies. Previous investments were focussed on companies located in Austria, Germany, Switzerland, and Netherlands. The fund has attracted several new institutional investors, including Amundi and Legal & General Capital which join Dutch pension funds PME and PMT, Pantheon and Eli Lilly and Company. The Forbion Growth Opportunities Fund II has already made four investments to date: Noema Pharma AG, VectivBio Holding AG,  Inversago Pharma Inc., F2G Ltd.

The two new funds brings the total of funds under management at Forbion to €3bn.